Study of NVN1000 Topical Gel and Topical Gel Vehicle in the Treatment of Moderate to Severe Acne Vulgaris

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01556698
Recruitment Status : Completed
First Posted : March 16, 2012
Last Update Posted : December 18, 2017
Information provided by (Responsible Party):
Novan, Inc.

Brief Summary:
The primary objective of this study is to compare the tolerability, safety and efficacy of NVN1000 Topical Gel and Topical Gel Vehicle in the treatment of subjects with moderate to severe acne vulgaris.

Condition or disease Intervention/treatment Phase
Acne Vulgaris Acne Drug: NVN1000 Topical Gel Drug: Topical Gel Vehicle Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Study Start Date : July 2011
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne
U.S. FDA Resources

Arm Intervention/treatment
Experimental: NVN1000 Topical Gel Drug: NVN1000 Topical Gel
Placebo Comparator: Topical Gel Vehicle Drug: Topical Gel Vehicle

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Years to 40 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Baseline IGA score of moderate (3) or severe (4)
  • Minimum of 20 but no more than 40 facial inflammatory lesions
  • Minimum of 20 but not more than 60 facial non-inflammatory lesions
  • No more than 2 facial nodules

Exclusion Criteria:

  • Dermatological conditions on the face that could interfere with clinical evaluations
  • Underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive
  • History of experiencing significant burning or stinging when applying any facial treatment
  • Female subjects, if they are pregnant,nursing mothers, or planning to become pregnant during the study
  • Have used estrogens or oral contraceptives for less than 90 days immediately preceding the Baseline visit, discontinued use of estrogens or oral contraceptives less than 90 days prior to Baseline,or planning to begin or discontinue use of this therapy during the treatment period
  • Have used medications and/or vitamins which are reported to exacerbate acne during the 180 days immediately preceding the Baseline visit
  • Use concomitantly over-the-counter (OTC) products that contain ingredients such as benzoyl peroxide,salicylic acid,alpha-hydroxy acid,retinol or glycolic acids
  • Have not undergone the specified washouts for topical preparations,systemic medications and procedures noted in the protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01556698

Dominican Republic
Instituto Dermatologico
Santo Domingo, Dominican Republic
Sponsors and Collaborators
Novan, Inc.
Principal Investigator: Daisy Blanco, MD Instituto Dermatológico

Responsible Party: Novan, Inc. Identifier: NCT01556698     History of Changes
Other Study ID Numbers: NI-AC001
First Posted: March 16, 2012    Key Record Dates
Last Update Posted: December 18, 2017
Last Verified: March 2012

Keywords provided by Novan, Inc.:
Acne Vulgaris

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases